Propanc Biopharma (PPCB) Registration filing summary

Company overview and business model

• Focuses on developing novel cancer treatments targeting pancreatic, ovarian, and colorectal cancers using a proprietary proenzyme therapy (PRP) designed to prevent recurrence and metastasis by targeting cancer stem cells.

• Lead product candidate PRP is in preclinical development, with plans to initiate a Phase Ib clinical trial in advanced solid tumor patients, subject to sufficient financing.

• Holds 84 granted or allowed patents and 6 pending applications globally for its proenzyme technology.

• Operates primarily from Australia, with research collaborations in Europe and a small team supported by consultants.

Financial performance and metrics

• No revenue-generating operations to date; accumulated deficit of $67.5 million as of December 31, 2024.

• Net loss for the six months ended December 31, 2024 was $784,493, down from $935,250 in the prior year period.

• Cash balance was $14,633 at December 31, 2024, with current liabilities of $4.15 million and a working capital deficit.

• Negative cash flows from operations; ongoing dependence on debt and equity financing to fund operations.

• Substantial doubt exists about the ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.6 million from the IPO (assuming $5.00 per unit), primarily allocated to working capital and general corporate purposes.

• Management retains broad discretion over the allocation of proceeds, with a focus on funding operating expenses and capital requirements for at least the next 12–18 months.